Can PRP or Antioxidants Slow Ovarian Aging?

PRP injections, stem-cell procedures, and antioxidant supplements have all produced enough ovarian-function signals to keep the "rejuvenation" story alive. None has shown that it slows natural ovarian aging in humans.

That distinction is more than semantic. A temporary change in anti-Müllerian hormone (AMH), antral follicle count (AFC), follicle-stimulating hormone (FSH), or oocyte yield during IVF may matter to a person pursuing fertility treatment. It does not prove that an intervention preserves ovarian reserve over years, delays menopause, or extends spontaneous fertility. Those are the outcomes an anti-aging claim would need to deliver.

What the current evidence actually studies

Most human regenerative research does not enroll healthy women moving through ordinary reproductive aging. It focuses on women with poor ovarian response during assisted reproduction or with primary ovarian insufficiency (POI), a clinical condition in which ovarian function declines or stops unusually early. These populations may be biologically informative, but they are not interchangeable with women experiencing typical age-related ovarian decline.

The interventions also vary widely. Intraovarian platelet-rich plasma (PRP) uses a concentrated preparation of a patient's own blood platelets, injected into ovarian tissue. Cellular approaches may use different cell sources, mobilization methods, adjunct products, and delivery routes. Grouping all of that under "ovarian rejuvenation" makes for tidy marketing and messy science.

Antioxidants are the low-complexity version of the idea: oxidative stress may contribute to reproductive aging, so reducing it might help. A 2024 systematic review and meta-analysis by Shang et al. examined antioxidants and fertility in women with ovarian aging. The review supports oxidative stress as a plausible target and identifies an uncertain, heterogeneous clinical literature. It does not show that oral antioxidants slow the natural rate of ovarian decline, preserve AMH or AFC trajectories over time, delay menopause, or protect spontaneous fertility.

That leaves antioxidant supplements in familiar territory: plausible mechanism, incomplete clinical proof. A bottle of vitamin C is easier to buy than an intraovarian injection, but convenience does not upgrade the evidence.

PRP can move short-term fertility markers

The most active human literature concerns autologous PRP in women with poor ovarian response, usually in IVF-related care. Three 2024 evidence syntheses reported pooled improvements in ovarian-reserve markers and IVF-linked outcomes after intraovarian PRP. The repeated findings include higher AMH and AFC, lower FSH, and increases in retrieved oocytes or embryo-related outcomes. These are signals that some ovaries in selected infertility settings may respond to biologic stimulation.

A 2024 systematic review and meta-analysis of 13 studies involving 1,289 women reported pooled improvements in AFC, AMH, FSH, estradiol, oocyte yield, and embryo yield after PRP. Its population was women classified as poor responders, largely in IVF contexts. The review also pooled clinical, spontaneous, and ongoing pregnancy prevalences. It did not establish whether PRP changes the long-term course of ovarian aging.

A separate 2024 meta-analysis of 10 studies and 793 participants found that intraovarian autologous PRP was associated with a statistically significant increase in AMH: standardized mean difference 0.44, 95% confidence interval 0.07 to 0.81, p=0.02. The confidence interval excludes no difference, but the result remains a surrogate outcome. AMH can help characterize ovarian reserve; it does not itself measure menopause timing, durable fertility, or biological age.

The same review evaluated FSH, AFC, oocyte number, and embryo number. Another 2024 PRP meta-analysis similarly examined poor ovarian responders and noted that treatment methods and results remained controversial. Differences in patient selection, injection protocols, concurrent IVF care, and chosen endpoints make it hard to treat pooled estimates as a single answer.

Why the positive PRP findings fall short of an anti-aging result

Many PRP studies use observational or before-and-after designs rather than randomized comparisons. In a before-and-after study, a participant's later result is compared with her own earlier result. That design can detect a change, but it cannot reliably show what caused it. Regression to the mean, selection bias, changes in IVF care, natural cycle-to-cycle variation, and publication bias can all make a treatment appear more effective than it is.

Follow-up creates another problem. Ovarian aging unfolds over years. Most studies instead measure short-term hormone values, follicle counts, egg retrieval, embryo counts, menstrual activity, or pregnancy-related outcomes. Each can be clinically relevant in context. None alone proves a slower ovarian-reserve trajectory.

Ovarian markers can improve after an intervention without showing that the ovary has become younger or will remain functional longer.

Safety evidence is also thin relative to the procedure. Intraovarian PRP is invasive, and cell-based approaches add further complexity. Small studies with limited adverse-event monitoring cannot answer practical questions about uncommon harms, reproducibility across clinics, or the role of operator technique.

POI research expands the hypothesis, not the proof

POI studies broaden the field beyond poor IVF response. A 2022 systematic review by Kuang et al. examined ovarian-function recovery after interventions including DHEA, PRP, hormone replacement therapy, and adipose-derived stromal cells. It covered one randomized controlled trial and five prospective studies. The review reported inconsistent findings and concluded that insufficient scientific evidence supported reliable recovery of ovarian function with any reviewed approach.

Across the inconsistent studies summarized in that review, 26 of 421 patients had spontaneous pregnancies, or 6.2%. That is a real clinical outcome, but it is not evidence that a particular treatment caused pregnancy or reliably restored function. The studies differed in intervention, population, follow-up, and design. POI also differs biologically from ordinary reproductive aging, so even a convincing POI treatment would still require separate research in naturally aging populations.

Cell therapies are earlier still

Cell-based ovarian interventions have an appealing premise: perhaps introduced cells, mobilized cells, or cell-derived factors can alter ovarian tissue function. A 2025 systematic review of cellular therapies in POI and poor ovarian reserve found a fragmented, low-certainty human evidence base. Studies differed in cell source, preparation, administration, and outcome measurement, with very limited high-quality comparative data.

A 2025 real-world Stem Cell Regenera study reported outcomes in women with ovarian failure after a combination protocol: G-CSF mobilization of peripheral-blood stem cells plus intraovarian injection of stem-cell-factor-enriched PRP. The study adds a human clinical signal in a population with few options. It cannot isolate the effect of G-CSF, mobilized cells, PRP, patient selection, or co-interventions because it was nonrandomized and combined several treatments.

Calling this "stem-cell ovarian rejuvenation" therefore implies a level of standardization and proof that the research does not have. It is a collection of experimental procedures, not an established anti-aging treatment class.

The practical verdict

Do not use antioxidant supplements, ovarian PRP, or cell-based ovarian procedures as anti-aging therapy. Antioxidants have not shown that they slow natural ovarian aging in humans. PRP and cellular approaches have produced short-term changes in ovarian markers and IVF-related outcomes in selected infertility populations, but those changes do not establish durable preservation of ovarian function.

For someone considering PRP or a regenerative procedure because of infertility or POI, the relevant question is narrower: does a reproductive endocrinologist think an experimental intervention is appropriate for this specific diagnosis, with its uncertain benefits, costs, and procedural risks? The present evidence supports research into ovarian modifiability. It does not support a human ovarian anti-aging protocol.